According to the Capital Securities Research Report, the core varieties of companies in the Chinese medicine industry benefit from aging, and the certainty of “volume increase” is strong. At the same time, due to the fact that exclusive varieties have certain bargaining power during collection, the price drop is limited. In the long run, performance is expected to maintain steady growth. At the same time, the traditional Chinese medicine industry has a long product life cycle. Some OTC products have strong self-financing properties, high production capacity flexibility, and there is no need for long-term high-intensity capital expenditure and R&D investment. Therefore, the stability of corporate free cash flow is good, and its high dividend rate is stable and sustainable.